LAVA Therapeutics (LVTX)
(Delayed Data from NSDQ)
$1.63 USD
0.00 (0.00%)
Updated Sep 23, 2024 03:59 PM ET
After-Market: $1.66 +0.03 (1.84%) 6:24 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
Income Statements
Fiscal Year end for LAVA Therapeutics NV falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 7 | 19 | 5 | 4 | NA |
Cost Of Goods | 3 | 0 | 0 | 0 | NA |
Gross Profit | 3 | 19 | 5 | 4 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 47 | 54 | 49 | 18 | 0 |
Income After Depreciation & Amortization | -43 | -35 | -44 | -15 | 0 |
Non-Operating Income | 2 | 3 | 0 | -1 | NA |
Interest Expense | 0 | 0 | 1 | 0 | NA |
Pretax Income | -42 | -32 | -45 | -15 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -42 | -32 | -45 | -16 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -42 | -32 | -45 | -16 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -44 | -34 | -43 | -14 | 0 |
Depreciation & Amortization (Cash Flow) | -1 | 1 | 1 | 0 | NA |
Income After Depreciation & Amortization | -43 | -35 | -44 | -15 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 26.73 | 25.92 | 19.76 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.57 | -1.23 | -2.30 | NA | NA |
Diluted Net EPS (GAAP) | -1.57 | -1.23 | -2.30 | -8,592.02 | NA |
Fiscal Year end for LAVA Therapeutics NV falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 6.99 | 0.35 | 0.05 | 5.14 |
Cost Of Goods | 0.00 | 0.00 | 0.15 | 0.01 | 2.39 |
Gross Profit | 0.00 | 6.99 | 0.20 | 0.04 | 2.75 |
SG&A, R&D, and Dept/Amort Expenses | 9.37 | 8.95 | 5.64 | 10.77 | 16.30 |
Income After SG&A, R&D, and Dept/Amort Expenses | -9.37 | -1.96 | -5.44 | -10.73 | -13.55 |
Non-Operating Income | 1.15 | 1.47 | -0.99 | 1.94 | 0.94 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -8.21 | -0.48 | -6.44 | -8.79 | -12.60 |
Income Taxes | 0.09 | 0.07 | 0.06 | 0.05 | 0.10 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -8.30 | -0.55 | -6.50 | -8.84 | -12.70 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -8.30 | -0.55 | -6.50 | -8.84 | -12.70 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 26.82 | 26.79 | 26.77 | 26.29 | 26.29 |
Diluted EPS Before Non-Recurring Items | -0.31 | -0.02 | -0.24 | -0.34 | -0.48 |
Diluted Net EPS (GAAP) | -0.31 | -0.02 | -0.22 | -0.34 | -0.48 |